Glynn Wilson
Known title: DirectorCIK: 0001405625
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BNKK Featured in Risk-Off Watchlist and Recent Session Movers. BNKK was named one of the top risk‑off stocks that could see a sharp decline this month. It also appeared among the top movers in both the after‑hours and regular trading sessions, showing heightened volatility. The stock’s high beta and recent revenue‑price divergence suggest it may be sensitive to market swings. Support sits near $1.40, a level that has been tested multiple times.
Transaction History
| CABR | ▼ Sell | Other | 1,500,000 | $750K | 3/27/2026 | View on chart |
| CABR | ▲ Buy | Grant | 126,720 | $0 | 12/11/2025 | View on chart |
| CABR | ▲ Buy | Grant | 45,872 | $0 | 12/11/2025 | View on chart |
| CVKD | ▼ Sell | Other | 50,000 | — | 1/24/2023 | View on chart |
| BNKK | ▼ Sell | Other | 14,124 | — | 7/26/2022 | View on chart |
| BNKK | ▼ Sell | Other | 14,124 | — | 7/26/2022 | View on chart |
| BNKK | ▲ Buy | Grant | 200,000 | $0 | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Cadrenal hires Tungsten Advisors to drive strategic process
Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.
Cadrenal hires Tungsten Advisors to drive strategic process. Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.